Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Page 6 of 10
Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kine...
Citation: Thrombosis Journal 2014 12:10
Venous thromboembolism (VTE) prophylaxis is underutilized for hospitalized patients. The primary objective of this study was to assess the impact of a continuing medical education (CME) program on thromboproph...
Citation: Thrombosis Journal 2014 12:9
Over the past several years a new era for patients requiring anticoagulation has arrived. The approval of new target specific oral anticoagulants offers practitioners several advantages over traditionally used...
Citation: Thrombosis Journal 2014 12:8
New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in so...
Citation: Thrombosis Journal 2014 12:7
The reported incidence of venous thromboembolism (VTE) varies considerably among studies. The primary aim of this study was to describe the incidence of VTE in relation to age and sex. The secondary aim was to...
Citation: Thrombosis Journal 2014 12:6
Vitamin K Antagonists (VKAs) are widely used in clinical practice and nearly 1% of the entire population receives oral anticoagulation at least once in life. However, the rate of prescription of anticoagulatio...
Citation: Thrombosis Journal 2014 12:5
Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, de...
Citation: Thrombosis Journal 2014 12:4
Chronic antithrombotic therapy involves the use of anticoagulants, antiplatelets given either as monotherapy or in combination for the prevention of thrombotic complications. The most feared and sometimes fata...
Citation: Thrombosis Journal 2014 12:3
The Editors of Thrombosis Journal would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).
Citation: Thrombosis Journal 2014 12:2
Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signa...
Citation: Thrombosis Journal 2014 12:1
Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mor...
Citation: Thrombosis Journal 2013 11:27
Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preven...
Citation: Thrombosis Journal 2013 11:26
The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, i...
Citation: Thrombosis Journal 2013 11:25
Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma samples o...
Citation: Thrombosis Journal 2013 11:24
Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induce...
Citation: Thrombosis Journal 2013 11:23
To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific co...
Citation: Thrombosis Journal 2013 11:22
Haemorrhage is the primary complication of anticoagulation therapy with the gastrointestinal, urinary and nasal tracts the most common sites of bleeding. Haematoma within solid organs is uncommon especially in...
Citation: Thrombosis Journal 2013 11:20
Plasma protein-C exerts anticoagulatory effects by inactivating factors V and VIII. Hereditary protein C deficiency is transmitted as an autosomal dominant disorder. Homozygous individuals usually develop purp...
Citation: Thrombosis Journal 2013 11:19
Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic ...
Citation: Thrombosis Journal 2013 11:21
Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action wh...
Citation: Thrombosis Journal 2013 11:18
Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most fre...
Citation: Thrombosis Journal 2013 11:17
The incidence of venous thromboembolic disease (VTED) is estimated to be, on average, 1–2 cases per 1,000 individuals per year worldwide. There are few data concerning the incidence rate (IR) of VTED in the Ar...
Citation: Thrombosis Journal 2013 11:16
New oral anticoagulants (NOAC) are approved for several indications for prophylaxis and treatment of venous thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without ne...
Citation: Thrombosis Journal 2013 11:15
Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism. Chronic anticoagulation is recommended for preventing those complications. Our study ai...
Citation: Thrombosis Journal 2013 11:14
Direct oral anticoagulants that target a single coagulation factor have been developed as an alternative to standard therapies with heparin and/or vitamin K antagonists. The purpose of this study was to derive...
Citation: Thrombosis Journal 2013 11:13
Microplate-based thrombin generation test (TGT) is widely used as clinical measure of global hemostatic potential and it becomes a useful tool for control of drug potency and quality by drug manufactures. Howe...
Citation: Thrombosis Journal 2013 11:12
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of whic...
Citation: Thrombosis Journal 2013 11:11
Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban d...
Citation: Thrombosis Journal 2013 11:10
Results of clotting tests used to measure the effect of old and new antithrombotic drugs can be expressed in different ways and this is considered as one of the sources of variability to explain the difference...
Citation: Thrombosis Journal 2013 11:9
New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therape...
Citation: Thrombosis Journal 2013 11:8
Heparin Induced Thrombocytopenia (HIT) is caused by antibodies that recognize platelet factor 4 (PF4) associated with polyanionic glycosaminoglycan drugs or displayed on vascular cell membranes. These antibodi...
Citation: Thrombosis Journal 2013 11:7
While the assessment of analytical precision within medical laboratories has received much attention in scientific enquiry, the degree of as well as the sources causing variation between them remains incomplet...
Citation: Thrombosis Journal 2013 11:6
Giant left atrium is a condition characterized by huge enlargement of the left atrium with a diameter exceeding 65mm. It is most commonly associated with long standing rheumatic mitral valve disease. We presen...
Citation: Thrombosis Journal 2013 11:5
Deep Vein Thrombosis (DVT) is an important cause of morbidity and is the first cause of maternal death after delivery in Western Nations. The risk of venous thromboembolism is present throughout the pregnancy ...
Citation: Thrombosis Journal 2013 11:4
Early treatment of disseminated intravascular coagulation (DIC) can be associated with improved patient outcomes. The Japanese Ministry of Health and Welfare (JMHW) and the International Society on Thrombosis ...
Citation: Thrombosis Journal 2013 11:3
Previous animal studies by us and others have indicated that catheter-administered plasmin or its des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolyti...
Citation: Thrombosis Journal 2013 11:2
The aim of the present study was to compare circulating levels of selected prothrombotic markers in patients suffering acute myocardial infarction (AMI) with and without left ventricular (LV) thrombus.
Citation: Thrombosis Journal 2013 11:1
Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist suc...
Citation: Thrombosis Journal 2012 10:24
Low Frequency Vibro-Percussion (LFVP) assists clearance of thrombi in catheter systems and when applied to the heart and timed to diastole is known to enhance coronary flow. However LFVP on a clotted coronary ...
Citation: Thrombosis Journal 2012 10:23
Dual antiplatelet treatment with aspirin and clopidogrel is the antithrombotic treatment recommended after an acute coronary syndrome and/or coronary artery stenting. The evidence for optimal antiplatelet ther...
Citation: Thrombosis Journal 2012 10:22
Hump-nosed pit viper (Genus Hypnale) is a medically important venomous snake in Sri Lanka and Southwestern India which causes significant morbidity and mortality. Envenoming of this snake results in hemostasti...
Citation: Thrombosis Journal 2012 10:21
Venous thromboembolism (VTE) is a leading cause of hospital-related deaths worldwide. However, the proportion of patients at risk of VTE who receive appropriate prophylaxis in Egypt is unknown. The ENDORSE stu...
Citation: Thrombosis Journal 2012 10:20
Postprandial hyperlipidemia and hyperglycemia have been related to cardiovascular events. Among different underlying mechanisms platelet activation seems to be responsible too. No comparable data between vario...
Citation: Thrombosis Journal 2012 10:19
This is a commentary discussing the article published in Thrombosis Journal by Subramanian et al. [Thrombosis Journal 2012, 10:15].
Citation: Thrombosis Journal 2012 10:18
Computer-assistance and self-monitoring lower the cost and may improve the quality of anticoagulation therapy. The main purpose of this clinical investigation was to use computer-assisted oral anticoagulant th...
Citation: Thrombosis Journal 2012 10:17
Coronary artery disease (CAD) is a major problem worldwide. Atherosclerosis and thrombosis underlying CAD involve multiple cell types. New and useful diagnostic markers are required. MicroRNAs (miRNAs) are a c...
Citation: Thrombosis Journal 2012 10:16
Bleeding remains a potentially lethal complication of cardio-pulmonary bypass (CPB) surgery. The purpose of this study was to obtain a better insight into in vitro thrombin generation in the context of CPB.
Citation: Thrombosis Journal 2012 10:15
Venous Thrombo-embolic disease is currently a hot topic especially in the UK. 25,000 patients per year die of Pulmonary Emboli (PE) in the United Kingdom (UK). Hip and knee arthroplasty surgery is associated w...
Citation: Thrombosis Journal 2012 10:14
Obesity, characterised by increased fat mass and is currently regarded as a pro-inflammatory state and often associated with increased risk of cardiovascular diseases (CVD) including Myocardial infarction. The...
Citation: Thrombosis Journal 2012 10:13
Cardiovascular disease with disturbances in the haemostatic system, might lead to thrombotic complications with clinical manifestations like acute myocardial infarction (AMI) and stroke. Activation of the coag...
Citation: Thrombosis Journal 2012 10:12
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Speed
51 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
102 days from submission to acceptance
45 days from acceptance to publication
Citation Impact
2.295- Impact Factor
1.235 - Source Normalized Impact per Paper (SNIP)
10.895 - SCImago Journal Rank (SJR)
Usage
270,557 Downloads
242 Altmetric mentions